Immunogenicity up to Age 5 Following Single- or Two-Dose Infant Primary Series of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine with Booster in South Africa: Extended RCT Follow-Up
Posted inClinical Updates news Pediatrics Public Health

Immunogenicity up to Age 5 Following Single- or Two-Dose Infant Primary Series of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine with Booster in South Africa: Extended RCT Follow-Up

This review synthesizes long-term immunogenicity data from a South African RCT comparing 1+1 and 2+1 infant PCV10 and PCV13 schedules. PCV13 1+1 schedules maintain durable immunity up to age 5, supporting schedule optimization in established programs.